Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Detection of Antigen Presentation by Murine Bone Marrow-Derived Dendritic Cells: Version 1

Enping Hong  1 , Marina A. Dobrovolskaia  1
In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May. NCL Method ITA-34.
2019 Feb.
Affiliations
Free Books & Documents
Review

Detection of Antigen Presentation by Murine Bone Marrow-Derived Dendritic Cells: Version 1

Enping Hong et al.
Free Books & Documents

Excerpt

Nanoparticles have been extensively tested as therapeutic vaccine delivery vehicles for the treatment of cancer. A key effort in this area is the delivery of antigens to antigen-presenting cells (APCs), such that tumor-specific peptides are presented in the context of class I major histocompatibility complex (MHC) molecules. The purpose of this protocol is to determine the ability of nanoparticles to deliver antigen to APCs, such that an antigenic class I peptide sequence is properly presented in the context of MHC. For the purposes of this assay, the model antigen ovalbumin (OVA) is used in the context of murine cells. The protocol requires the synthesis of nanoparticles that deliver SIINFEKL (OVA257-264), the immunodominant class I peptide derived from OVA, either in its peptide form or as part of a larger molecule (such as the whole OVA protein). The 25-D1.16 antibody, which binds to SIINFEKL presented in the context of the mouse H2-Kb MHC molecule [1], is used to detect antigen presentation on APCs after nanoparticle delivery. The results of this protocol may be used to infer the ability of the nanoparticle system to deliver other similar antigens.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Porgador, A., et al.., Localization, Quantitation, and In Situ Detection of Specific Peptide–MHC Class I Complexes Using a Monoclonal Antibody. Immunity, 1997. 6: p. 715–726. - PubMed
    1. Shen, Z., et al.., Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. The Journal of Immunology, 1997. 158: p. 2723–2730. - PubMed
    1. Dobrovolskaia, M.A. and McNeil S.E., Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release, 2013. 172(2): p. 456–66. - PMC - PubMed

LinkOut - more resources